

CORRIGENDUM

EBV-induced human CD8⁺ NKT cells synergize CD4⁺ NKT cells suppressing EBV-associated tumors upon induction of Th1 bias

Wei Xiao, Li Li, Rui Zhou, Ruijing Xiao, Yujuan Wang, Xiang Ji, Mengjun Wu, Lan Wang, Wei Huang, Xiaoling Zheng, Xinti Tan, Lang Chen, Tao Xiong, Jie Xiong, Youxin Jin, Jinquan Tan and Yuling He

Cellular & Molecular Immunology (2011) 8, 368; doi:10.1038/cmi.2011.66

Correction to: *Cellular & Molecular Immunology* (2009) 6, 367–379; doi:10.1038/cmi.2009.48

The authors inadvertently published histograms in the fourth panel to the right in both rows of Figure 4c that were actually the data of CD8⁺ NKT cells from EBV-exposed CD8⁺ NKT

cell-transferred, or EBV-exposed CD4⁺ and CD8⁺ NKT-transferred hu-thym-SCID chimeras. The corrected figure included here contains the histograms that correctly represent the data of T cells from EBV-exposed CD4⁺ and CD8⁺ NKT-transferred hu-thym-SCID chimeras. Since the fourth panels to the right in both rows of Figure 4c show the cellular proliferation using the CFSE labeling technique, the histogram substitutions do not alter the conclusions that were drawn from the original data. The authors would like to apologize for their mistake.




Figure 4 Proliferation and cytokine expression by CD4⁺ and CD8⁺ NKT cells, and T cells from EBV-sensitized chimeras *in vivo* in response to EBV re-challenge. The SCID mice were adoptively transferred *i.v.* with the different combinations of the immune cells purified from EBV-exposed hu-thym-SCID chimeras (CD4⁺, CD8⁺ NKT cells, CD4⁺CD8⁺ NKT cells transferred) as described in Methods. On day 3 post-reconstitution, EBV-sensitized chimeras were re-challenged *i.v.* with EBV (10⁷ pfu) and maintained for further 4 days, or left unchallenged (Nil). **(a)** Proliferation of chimeric CD4⁺ and CD8⁺ NKT cells. In this experiment, the purified thymic CD4⁺ or CD8⁺ NKT cells from EBV-exposed chimeras were labeled with CFSE prior to the transfer into the SCID mice. After EBV re-challenge, EBV-sensitized chimeras were euthanized. The PBMC were stained with appropriate tetramer/Abs, and analyzed by flow cytometry. ND, no determination. Data were representative ($n=6$). **(b)** IFN- γ and IL-4 expression by CD4⁺ and CD8⁺ NKT cells. As described above, EBV-sensitized chimeras were euthanized after EBV re-challenge. The indicated cytokines in NKT cells were examined by tetra-color (cytokine Ab, CD4 Ab, CD8 Ab, CD1d tetramer) intracellular flow cytometry. The experimental and analysis schemes were illustrated in the leftmost panel of Figure 3 (without tumor-implantation). ND, no determination. Data were mean \pm s.d. ($n=5$). * $P<0.001$. **(c)** Proliferation of EBV-specific CD3⁺CD56⁻CD161⁻ T cells. The EBV-sensitized chimeras were established as described above. The purified spleen CD3⁺CD56⁻CD161⁻ T cells were labeled with CFSE prior to transfer into the SCID mice. The EBV-sensitized chimeras were euthanized after EBV re-challenges, and PBMC were stained with appropriate tetramer/Abs, then analyzed by flow cytometry for cell proliferation. Data were mean \pm s.d. ($n=5$). * $P<0.001$. **(d)** IFN- γ and IL-4 expression by CD3⁺ T cells. Analysis was performed as described above. The indicated cytokines in CD3⁺ T cells were examined by intracellular flow cytometry. Data were mean \pm s.d. ($n=5$). * $P<0.001$.